Sexually Transmitted Diseases Diagnostics Market Size to Hit USD 21.44 Bn by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Sexually Transmitted Diseases Diagnostics Market

5.1. COVID-19 Landscape: Sexually Transmitted Diseases Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Sexually Transmitted Diseases Diagnostics Market, By Disease Type/Pathogen

8.1. Sexually Transmitted Diseases Diagnostics Market Revenue and Volume, by Disease Type/Pathogen

8.1.1. Chlamydia trachomatis

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Neisseria gonorrhoeae (Gonorrhea)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Human Immunodeficiency Virus (HIV)

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Human Papillomavirus (HPV)

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Herpes Simplex Virus (HSV-1 & HSV-2)

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Syphilis (Treponema pallidum)

8.1.6.1. Market Revenue and Volume Forecast

8.1.7. Trichomoniasis

8.1.7.1. Market Revenue and Volume Forecast

8.1.8. Hepatitis B & C

8.1.8.1. Market Revenue and Volume Forecast

8.1.9. Mycoplasma genitalium

8.1.9.1. Market Revenue and Volume Forecast

8.1.10. Others

8.1.5.10.1. Market Revenue and Volume Forecast

Chapter 9. Global Sexually Transmitted Diseases Diagnostics Market, By Diagnostic Technology/Type

9.1. Sexually Transmitted Diseases Diagnostics Market Revenue and Volume, by Diagnostic Technology/Type

9.1.1. Laboratory-Based Tests

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Rapid Point-of-Care (POC) Tests

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Other Technologies

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Sexually Transmitted Diseases Diagnostics Market, By Sample Type

10.1. Sexually Transmitted Diseases Diagnostics Market Revenue and Volume, by Sample Type

10.1.1. Blood Samples

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Urine Samples

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Swab Samples (Oral, Vaginal, Urethral)

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Cervical/Vaginal Lavage

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Semen/Prostatic Fluid

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Sexually Transmitted Diseases Diagnostics Market, By Location of Testing

11.1. Sexually Transmitted Diseases Diagnostics Market Revenue and Volume, by Location of Testing

11.1.1. Laboratory Testing (Hospitals/Diagnostic Labs)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Clinics & Public Health Centers

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Home-Based Testing / Self-testing Kits

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Sexually Transmitted Diseases Diagnostics Market, By End User

12.1. Sexually Transmitted Diseases Diagnostics Market Revenue and Volume, by End User

12.1.1. Hospitals & Clinics

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Diagnostic Laboratories

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Home Users / Individuals

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Government & Public Health Agencies

12.1.4.1. Market Revenue and Volume Forecast

12.1.5. NGOs and STI Programs

12.1.5.1. Market Revenue and Volume Forecast

12.1.6. Others

12.1.6.1. Market Revenue and Volume Forecast

Chapter 13. Global Sexually Transmitted Diseases Diagnostics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.1.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.1.3. Market Revenue and Volume Forecast, by Sample Type

13.1.4. Market Revenue and Volume Forecast, by Location of Testing

13.1.5. Market Revenue and Volume Forecast, by End User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.1.6.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.1.6.3. Market Revenue and Volume Forecast, by Sample Type

13.1.6.4. Market Revenue and Volume Forecast, by Location of Testing

13.1.6.5. Market Revenue and Volume Forecast, by End User

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.1.7.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.1.7.3. Market Revenue and Volume Forecast, by Sample Type

13.1.7.4. Market Revenue and Volume Forecast, by Location of Testing

13.1.7.5. Market Revenue and Volume Forecast, by End User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.2.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.2.3. Market Revenue and Volume Forecast, by Sample Type

13.2.4. Market Revenue and Volume Forecast, by Location of Testing

13.2.5. Market Revenue and Volume Forecast, by End User

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.2.6.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.2.6.3. Market Revenue and Volume Forecast, by Sample Type

13.2.7. Market Revenue and Volume Forecast, by Location of Testing

13.2.8. Market Revenue and Volume Forecast, by End User

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.2.9.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.2.9.3. Market Revenue and Volume Forecast, by Sample Type

13.2.10. Market Revenue and Volume Forecast, by Location of Testing

13.2.11. Market Revenue and Volume Forecast, by End User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.2.12.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.2.12.3. Market Revenue and Volume Forecast, by Sample Type

13.2.12.4. Market Revenue and Volume Forecast, by Location of Testing

13.2.13. Market Revenue and Volume Forecast, by End User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.2.14.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.2.14.3. Market Revenue and Volume Forecast, by Sample Type

13.2.14.4. Market Revenue and Volume Forecast, by Location of Testing

13.2.15. Market Revenue and Volume Forecast, by End User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.3.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.3.3. Market Revenue and Volume Forecast, by Sample Type

13.3.4. Market Revenue and Volume Forecast, by Location of Testing

13.3.5. Market Revenue and Volume Forecast, by End User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.3.6.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.3.6.3. Market Revenue and Volume Forecast, by Sample Type

13.3.6.4. Market Revenue and Volume Forecast, by Location of Testing

13.3.7. Market Revenue and Volume Forecast, by End User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.3.8.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.3.8.3. Market Revenue and Volume Forecast, by Sample Type

13.3.8.4. Market Revenue and Volume Forecast, by Location of Testing

13.3.9. Market Revenue and Volume Forecast, by End User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.3.10.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.3.10.3. Market Revenue and Volume Forecast, by Sample Type

13.3.10.4. Market Revenue and Volume Forecast, by Location of Testing

13.3.10.5. Market Revenue and Volume Forecast, by End User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.3.11.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.3.11.3. Market Revenue and Volume Forecast, by Sample Type

13.3.11.4. Market Revenue and Volume Forecast, by Location of Testing

13.3.11.5. Market Revenue and Volume Forecast, by End User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.4.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.4.3. Market Revenue and Volume Forecast, by Sample Type

13.4.4. Market Revenue and Volume Forecast, by Location of Testing

13.4.5. Market Revenue and Volume Forecast, by End User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.4.6.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.4.6.3. Market Revenue and Volume Forecast, by Sample Type

13.4.6.4. Market Revenue and Volume Forecast, by Location of Testing

13.4.7. Market Revenue and Volume Forecast, by End User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.4.8.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.4.8.3. Market Revenue and Volume Forecast, by Sample Type

13.4.8.4. Market Revenue and Volume Forecast, by Location of Testing

13.4.9. Market Revenue and Volume Forecast, by End User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.4.10.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.4.10.3. Market Revenue and Volume Forecast, by Sample Type

13.4.10.4. Market Revenue and Volume Forecast, by Location of Testing

13.4.10.5. Market Revenue and Volume Forecast, by End User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.4.11.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.4.11.3. Market Revenue and Volume Forecast, by Sample Type

13.4.11.4. Market Revenue and Volume Forecast, by Location of Testing

13.4.11.5. Market Revenue and Volume Forecast, by End User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.5.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.5.3. Market Revenue and Volume Forecast, by Sample Type

13.5.4. Market Revenue and Volume Forecast, by Location of Testing

13.5.5. Market Revenue and Volume Forecast, by End User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.5.6.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.5.6.3. Market Revenue and Volume Forecast, by Sample Type

13.5.6.4. Market Revenue and Volume Forecast, by Location of Testing

13.5.7. Market Revenue and Volume Forecast, by End User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Disease Type/Pathogen

13.5.8.2. Market Revenue and Volume Forecast, by Diagnostic Technology/Type

13.5.8.3. Market Revenue and Volume Forecast, by Sample Type

13.5.8.4. Market Revenue and Volume Forecast, by Location of Testing

13.5.8.5. Market Revenue and Volume Forecast, by End User

Chapter 14. Company Profiles

14.1. Becton, Dickinson and Company (BD)

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Siemens Healthineers

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Thermo Fisher Scientific Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. OraSure Technologies, Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Trinity Biotech

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Chembio Diagnostics, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Fujirebio (H.U. Group Holdings)

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Sekisui Diagnostics

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Nanjing Vazyme Medical Technology Co., Ltd.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Atlas Genetics (now part of Binx Health)

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global sexually transmitted diseases (STD) diagnostics market is expected to increase from USD 10.66 billion in 2024 to USD 21.44 billion by 2034.

The sexually transmitted diseases (STD) diagnostics market is expected to grow at a compound annual growth rate (CAGR) of around 7.24% from 2025 to 2034.

The major players in the sexually transmitted diseases (STD) diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche AG, Becton, Dickinson and Company (BD), Hologic, Inc., Thermo Fisher Scientific Inc., bioMérieux SA, Siemens Healthineers, Bio-Rad Laboratories, Inc., Qiagen N.V., Cepheid (a Danaher company), OraSure Technologies, Inc., Trinity Biotech, Chembio Diagnostics, Inc., GenMark Diagnostics, QuidelOrtho Corporation, Fujirebio (H.U. Group Holdings), MedMira Inc., Sekisui Diagnostics, Nanjing Vazyme Medical Technology Co., Ltd., Atlas Genetics (now part of Binx Health).

The driving factors of the sexually transmitted diseases (STD) diagnostics market are due to increasing public health awareness, enhanced access to screening programs, and digital innovations, including nucleic acid amplification tests and multiplex polymerase chain reaction tests.

North America region will lead the global sexually transmitted diseases (STD) diagnostics market during the forecast period 2025 to 2034.